{"title": "BRIEF-Clearside Biomedical announces first patient randomized in phase 2 clinical trial of CLS-TA", "author": "Reuters Staff", "url": "https://www.reuters.com/article/brief-clearside-biomedical-announces-fir-idUKASA09WQF", "hostname": "reuters.com", "description": "* Clearside Biomedical announces first patient randomized in phase 2 clinical trial of cls-ta used together with eylea in patients with diabetic macular edema", "sitename": "Reuters", "date": "2017-07-11", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "July 11 (Reuters) - Clearside Biomedical Inc\n* Clearside Biomedical announces first patient randomized in phase 2 clinical trial of cls-ta used together with eylea in patients with diabetic macular edema\n* Clearside Biomedical Inc - currently expect to report three-month preliminary data in first half of 2018 Source text for Eikon: Further company coverage:\nOur Standards:\n[The Thomson Reuters Trust Principles.](http://thomsonreuters.com/en/about-us/trust-principles.html)", "language": null, "image": "https://s1.reutersmedia.net/resources_v2/images/rcom-default.png?w=800", "pagetype": "article", "links": ["https://www.thomsonreuters.com/en/global-gateway.html", "https://www.thomsonreuters.com/en/login.html", "https://reuters.zendesk.com/hc/en-us/articles/216467423-Contact-Reuters", "https://reuters.zendesk.com/hc/en-us", "https://www.reuters.com/news/archive/americasRegulatoryNes", "http://thomsonreuters.com/en/about-us/trust-principles.html", "//www.reuters.com/tools/mobile", "//newslink.reuters.com/join/subscribe", "//sales.reuters.com/en/ ", "//www.reuters.com/advertising-guidelines", "https://www.thomsonreuters.com/en/privacy-statement.html#cookies", "//www.reuters.com/terms-of-use", "https://www.thomsonreuters.com/en/privacy-statement.html", "javascript:window.OneTrust.ToggleInfoDisplay();", "https://www.reuters.com/info/disclaimer", "https://thomsonreuters.com/copyright/"]}